$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Analysis of the reasons why the domestic launch of Elacetrant has been delayed many times
2026-02-01 22:25:32
Check Details
How much does a box of F/TAF cost and price comparison and reference of different purchase channels
2026-02-01 22:25:32
Check Details
How long does it take to take Febuxostat (Febuxostat) before you can safely stop taking it and what you need to pay attention to when stopping taking it
2026-02-01 22:25:32
Check Details
Furmonertinib belongs to which generation of targeted drugs and an introduction to its technical advantages
2026-02-01 22:25:32
Check Details
Analysis of the domestic market price of ensifentrine-Ohtuvayre and its differences across regions
2026-02-01 22:25:32
Check Details
Analysis of the mechanism of action and acne treatment effect of Roaccutane (isotretinoin) soft capsules
2026-02-01 22:25:32
Check Details
Detailed explanation of the anti-cancer mechanism of Doxorubicin and its application value in tumor treatment
2026-02-01 22:25:32
Check Details
Can Platinib (Pujihua) be used in conjunction with the immunotherapy regimen?
2026-02-01 22:25:32
Check Details
Research progress on the possibility of capmatinib (Touradida) treating other types of cancer
2026-02-01 22:25:32
Check Details
Analysis of the differences in treatment strategies between sotoracib (AMG 510) and osimertinib
2026-02-01 22:25:32
Check Details
Study results on whether adagrasib (Krazati) needs to be combined with other drugs
2026-02-01 22:25:32
Check Details
Detailed description of Pimitespib’s launch time and drug purchasing channels in China
2026-02-01 22:25:32
Check Details
1
2
...
2152
2153
2154
2155
2156
2157
2158
...
10228
10229
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Cemiplimab: A PD-1 Checkpoint Inhibitor for Skin Cancers and Non-Small Cell Lung Cancer
2
Nintedanib: A Multi-Target Antifibrotic Agent for Slowing Pulmonary Fibrosis Progression
3
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
4
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
5
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
6
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
7
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
8
Valganciclovir (Valcyte) in Post-Transplant CMV Management: A Comprehensive Guide
9
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
10
Long-Term Anagrelide Use: Common Adverse Effects and Key Monitoring Considerations
11
Resmetirom Indication Clarification: Approved for NASH Fibrosis, Not Hepatitis B Cirrhosis
12
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy